Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Wei Chern Gavin FongAdnan AzimDeborah KnightHeena MistryAnna FreemanMae FelongcoAref KyyalyMatthew HarveyPatrick DennisonHongmei ZhangPeter HowarthSyed Hasan ArshadRamesh J KurukulaaratchyPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021)
In a difficult asthma cohort, Omalizumab and Mepolizumab were used in distinct clinical phenotypes but were both multidimensionally efficacious. Certain baseline clinical characteristics were associated with poorer biologic responses, such as psychological co-morbidity, which may assist clinicians in biologic selection. These characteristics also emphasize the need for comprehensive approaches to support these patients.